Overview
Actively managed equity fund based on an equity portfolio investing in selected Chinese companies.
The manager is given great flexibility to take focused views on the most attractive stocks and exploit the best opportunities, unconstrained by the reference index.
Diversified across sectors offering broad coverage of the onshore and offshore Chinese equity market.
The portfolio manager is not tied to the benchmark in terms of investment selection or weight.
Benefits
Easy access to investment opportunities provided by a rapidly growing Chinese economy. Investors gain access to all classes of shares, providing exposure to onshore and offshore China equities: A, B and H shares, Red chips, P chips and ADRs.
Due to the significant deviation from the reference index, the fund offers the potential to outperform the reference index.
Investors benefit from UBS being one of the few asset managers with a truly global investment platform.
The experienced portfolio management team can leverage local investment expertise in the Chinese market via our joint venture UBS SDIC in China.
Risks
Features
| Product category |
Equity Asia |
| Product domicile |
Luxembourg
|
| Portfolio management |
UBS SA国际传谋 (Hong Kong) Ltd., Hong Kong
|
| Fund management |
UBS SA国际传谋 (Europe) S.A., Luxembourg
|
| Custodian bank |
UBS Europe SE, Luxembourg Branch
|
| Representative for products established under foreign law |
UBS Fund Management (Switzerland) AG
|
| Legal form |
SICAV
|
| Day of inception |
February 25, 2019
|
| Currency of account |
USD
|
| Close of financial year |
May 31
|
| SFDR Classification |
Art.8
|
| Issue / redemption |
daily
|
| Distribution |
Reinvestment
|
| Maturity |
Open end
|
| Ongoing costs p.a. |
0.06% p.a.
|
| Flat fee |
0.00% p.a.
|
| Management fee |
0.00% p.a.
|
| Total expense ratio (TER) |
0.03% p.a.
|
| Minimum investment |
n.a.
|
| Reference Index / Benchmark |
MSCI China All-Share (net div. reinv.)
|
| Cut-Off Time |
13:00h(CET)
|
| Securities no. |
41207674
|
| ISIN |
LU1807302572
|
| Bloomberg Ticker |
UBACIXA LX
|
Performance and Prices
Percentage growth
as of April 23, 2026| USD(%) | CHF(%) | EUR(%) | |
| YTD | -2.06 | -3.12 | -1.78 |
| 1M | |||
| 3M | |||
| 6M | |||
| 1Y | |||
| 2Y | 29.05 | 12.81 | 13.78 |
| 3Y | |||
| 5Y | -30.05 | -40.22 | -28.03 |
| ø p.a.5Y | -6.90 | -9.78 | -6.37 |
Current data
| Net asset value | 24.04.2026 | USD 113.77 |
| High - last 12 months | 29.01.2026 | USD 122.86 |
| Low - last 12 months | 29.04.2025 | USD 97.54 |
| Assets of the unit class in mn | 24.04.2026 | USD 90.66 |
| Total product assets in mn | 24.04.2026 | USD 1,200.53 |
|
Date
|
2 years
|
5 years
|
|
| Total risk reference index / benchmark | 31.03.2026 | 20.14% | 23.51% |
| Sharpe Ratio | 31.03.2026 | 0.51 | -0.40 |
| Risk Free Rate | 31.03.2026 | 4.55% | 3.51% |
Structures
By the 10 largest equity positions (in %, as of March 31, 2026)
|
|
|
| TENCENT HOLDINGS LTD | 9.47 |
| KWEICHOW MOUTAI CO LTD A | 8.26 |
| NETEASE INC | 8.13 |
| ALIBABA GROUP HOLDING LTD | 5.71 |
| CHINA MERCHANTS BANK-H | 5.33 |
| FAR EAST HORIZON LTD | 4.71 |
| AIA GROUP LTD | 4.41 |
| PING AN INSURANCE GROUP CO-H | 3.61 |
| CHINA MOBILE LIMITED | 2.61 |
| CSPC PHARMACEUTICAL GROUP LT | 2.52 |
Fees
Distributions
Sales Authorisations
Literature
|
Document type
|
Document Language
|
|||
| Prospectus |
|
|
||
| Key Information Document |
|
|
|
|
| Past performance |
|
|
|
|
| Previous performance scenario |
|
|
|
|
| Statutes / Management regulations |
|
|
||
| ESG Disclosure |
|
|||
| SFDR Pre-Contractual Annex |
|
|
Document type
|
Document Language
|
||
| Annual report |
|
|
|
| SFDR Periodic Report Annex |
|
||
| Semi-annual report |
|
|
|